DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.96

Change

-0.02 (-0.22)%

Market Cap

USD 0.17B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.16 (+0.16%)

USD 16.05B
VGS:AU Vanguard MSCI International Sh..

+0.47 (+0.37%)

USD 8.59B
IVV:AU iShares Core S&P 500 AUD

+0.15 (+0.27%)

USD 8.26B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.25 (+0.46%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

+0.06 (+0.18%)

USD 5.96B
STW:AU SPDR® S&P/ASX 200 Fund

+0.16 (+0.21%)

USD 5.61B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.35 (+0.88%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

+0.26 (+0.61%)

USD 4.83B
A200:AU BetaShares Australia 200

+0.09 (+0.07%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+1.09 (+0.26%)

USD 4.70B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.13% 76% C+ 73% C
Dividend Return 3.15% 61% D- 50% F
Total Return 16.28% 79% B- 74% C
Trailing 12 Months  
Capital Gain 14.87% 62% D 71% C-
Dividend Return 3.20% 45% F 36% F
Total Return 18.07% 61% D- 71% C-
Trailing 5 Years  
Capital Gain 50.08% 86% B+ 78% C+
Dividend Return 10.78% 46% F 34% F
Total Return 60.87% 84% B 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 6.94% 77% C+ 58% F
Dividend Return 8.47% 74% C 57% F
Total Return 1.53% 50% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 8.36% 67% D+ 93% A
Risk Adjusted Return 101.28% 97% N/A 98% N/A
Market Capitalization 0.17B 34% F 66% D+

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.